Obecabtagene Autoleucel Effective Treatment for Adults with B-ALL
While blinatumomab and inotuzumab ozogamicin can increase the likelihood of response in patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), most patients require ...
Combination of Venetoclax, Lower Intensity CPX-351 Shows Positive Results in Early-Stage AML Study
A new clinical trial combining lower-intensity CPX-351 therapy plus venetoclax as induction therapy has shown positive initial results among patients with acute myeloid leukemia ...
Blinatumomab Added to Chemotherapy Is New Standard of Care in Newly Diagnosed Childhood SR B-ALL
During a plenary session of the 66th American Society of Hematology Annual Meeting and Exposition, Rachel Rau, MD, associate professor of pediatrics at ...
Socioeconomic Factors, Education Levels Affect Access to AlloHCT for AML
Previous studies have determined that allogeneic hematopoietic cell transplantation (alloHCT) is a curative treatment for acute myeloid leukemia ...
Geriatric Assessment-Guided Conditioning Reduced Non-Relapse Mortality for Transplant in Myeloid Malignancies
Use of a geriatric assessment (GA)-driven, risk-adapted approach to select conditioning intensity for older patients with myeloid malignancies eligible for allogeneic hematopoietic transplantation ...
Addition of Induction Gilteritinib May Provide Some Benefit for Newly Diagnosed FLT3-Mutated AML
Induction therapy with combination chemotherapy plus gilteritinib yielded an excellent compositive complete remission (CRc) rate with no treatment-related deaths in patients with newly diagnosed ...
Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib
Historically, hematologists have feared Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) because of its poor prognosis. However, new research suggests that dual ...
Weekly Low-Dose Regimen of Decitabine and Venetoclax as Effective as Higher Dose
A metronomic, low-dose schedule of decitabine and venetoclax was deemed to be a safe and effective treatment for patients with myeloid malignancies. Patients with acute myeloid leukemia ...
New Risk Classification Stratifies Outcomes in Older Intensively Treated Patients with AML
The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with acute myeloid leukemia (AML) and high-risk ...
Genetics-Based Risk Model to Stratify Survival Outcomes of Patients With AML Treated With Venetoclax- Azacitidine
An analysis of treatment-naïve patients with acute myeloid leukemia (AML) receiving venetoclax plus azacitidine demonstrates that the European LeukemiaNet (ELN) AML genetic risk classification systems ...
